Yahoo奇摩 網頁搜尋

搜尋結果

1. www.straitstimes.com › singapore › askst-what-does-moderna-s-2askST: What you need to know about Moderna’s new ...

   www.straitstimes.com › singapore › askst-what-does-moderna-s-2

   • 庫存頁面

   1 天前 · Jun 12, 2024, 05:15 PM. SINGAPORE – Moderna said on June 10 that its combination Covid-19 and influenza vaccine results in better antibody response than flu and Covid-19 vaccines taken ...

2. health.economictimes.indiatimes.com › news › pharmaModerna’s Influenza vaccine Phase III data gives ...

   health.economictimes.indiatimes.com › news › pharma

   • 庫存頁面

   1 天前 · New Delhi: US based vaccine developer, Moderna announced the Phase III trial data for its COVID-19/influenza combination vaccine, mRNA-1083.The data suggest that the vaccine has potential to ...

3. site.financialmodelingprep.com › market-news › modernaModerna's Promising Developments and Analyst Optim...

   site.financialmodelingprep.com › market-news › moderna

   • 庫存頁面

   1 天前 · Moderna's experimental COVID-19-influenza combination vaccine, mRNA-1083, shows promising results in a late-stage study, potentially simplifying vaccination protocols. The FDA approval of Moderna's mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for adults aged 60 years and older, despite leading to a stock price decrease, underscores the company's commitment to addressing ...

4. www.indiatoday.in › health › storyModerna's Covid-flu combo vaccine superior to separate ...

   www.indiatoday.in › health › story

   • 庫存頁面

   1 天前 · The pharmaceutical giant Moderna announced that its combination vaccine for Covid-19 and influenza generated a stronger immune response in adults aged 50 and older compared to separate shots for each virus in a Phase 3 trial. A phase 3 trial is a late-stage clinical study designed to assess the efficacy and safety of a new treatment, drug, or ...

5. www.forbes.com › sites › alexknappInnovationRx: Tarsus Pharmaceuticals Takes Aim At ...

   www.forbes.com › sites › alexknapp

   • 庫存頁面

   14 小時前 · In both age groups, Moderna said participants receiving the combination vaccine generated “significantly higher immune responses” against a number of influenza strains, as well as against Sars ...

6. es.investing.com › news › stock-market-newsOppenheimer aumenta la valoración de Moderna tras la ...

   es.investing.com › news › stock-market-news

   • 庫存頁面

   1 天前 · Oppenheimer ha aumentado su precio objetivo para Moderna (MRNA) tras el éxito de la compañía farmacéutica estadounidense en la obtención de la aprobación de la Food and Drug Administration ...

7. vn.investing.com › news › stock-market-newsOppenheimer tăng dự báo giá của Moderna sau kh ...

   vn.investing.com › news › stock-market-news

   • 庫存頁面

   1 天前 · Thị trường đang đi lên. Mỗi thành viên trong cộng đồng hơn 120 nghìn người này đều biết họ nên làm gì. Oppenheimer đã tăng mục tiêu giá đối với Moderna (NASDAQ: MRNA) sau khi Cơ quan Quản lý Thực phẩm và Dược phẩm Hoa Kỳ (FDA) cấp phép gần đây cho vắc xin của Moderna đối với virus hợp bào hô hấp (RSV), được ...